Your browser doesn't support javascript.
loading
Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.
Izikson, Ruvim; Brune, Daniel; Bolduc, Jean-Sébastien; Bourron, Pierre; Fournier, Marion; Moore, Tamala Mallett; Pandey, Aseem; Perez, Lucia; Sater, Nessryne; Shrestha, Anju; Wague, Sophie; Samson, Sandrine I.
Afiliação
  • Izikson R; Sanofi Pasteur, Swiftwater, PA, USA. Electronic address: ruvim.izikson@sanofi.com.
  • Brune D; Accelerated Enrollment Solutions, Peoria, IL, USA.
  • Bolduc JS; Sanofi Pasteur, Marcy l'Etoile, France.
  • Bourron P; Sanofi Pasteur, Lyon, France.
  • Fournier M; Sanofi Pasteur, Lyon, France.
  • Moore TM; Sanofi Pasteur, Swiftwater, PA, USA.
  • Pandey A; Sanofi Pasteur, Swiftwater, PA, USA.
  • Perez L; Sanofi Pasteur, Swiftwater, PA, USA.
  • Sater N; Sanofi Pasteur, Marcy l'Etoile, France.
  • Shrestha A; Sanofi Pasteur, Swiftwater, PA, USA.
  • Wague S; Sanofi Pasteur, Lyon, France.
  • Samson SI; Sanofi Pasteur, Lyon, France.
Lancet Respir Med ; 10(4): 392-402, 2022 04.
Article em En | MEDLINE | ID: mdl-35114141
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Vírus da Influenza A Subtipo H1N1 / COVID-19 Tipo de estudo: Clinical_trials / Guideline Limite: Aged / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Vírus da Influenza A Subtipo H1N1 / COVID-19 Tipo de estudo: Clinical_trials / Guideline Limite: Aged / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article